Alltrna has raised another $109 million in a series B to fund the Flagship Pioneering biotech's mission to "stop codon disease" with potential benefits for a range of genetic diseases caused by ...

For disorders driven by a known genetic component, research understandably focuses on developing a drug targeting that genetic signature. When that works, the outcome benefits patients but the end ...

Alltrna is advancing a new class of genetic medicines based on the power of tRNA biology to universally treat Stop Codon Disease, which encompasses thousands of genetic diseases caused by a premature ...

RNA therapeutics target translation rather than DNA, aiming to correct shared protein production errors. By enabling cells to read through premature stop codons, engineered tRNAs could restore ...

Between 10 to 15% of all genetic diseases have the same underlying cause: a nonsense mutation. 1 This type of mutation results from a stop codon in the middle of a gene sequence, which terminates ...

A 3D illustration of a transfer RNA molecule hovering over a messenger RNA. Transfer RNA acts as an adaptor to convert messenger RNA codons into amino acids during protein synthesis. Credit: ...

An estimated 170,000 Australians were diagnosed with cancer in 2025. Many people know the causes of cancer are partly genetic. But how do your genes, which contribute so much of what makes you you, ...

Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF/MEK inhibitors. This is an ASCO Meeting Abstract from the 2024 ASCO ...